Plain-English answer
Fee-for-service in China is the traditional payment logic under which hospitals and providers receive payment for individual services, drugs, tests, and procedures. It helped finance hospitals when direct public subsidies were limited, but it also created incentives for volume, tests, drugs, and revenue-seeking behavior. Much of China's payment reform is designed to reduce these distortions.
Policy context
Public hospitals historically relied on service revenue, drug markups, diagnostics, and consumables to support operations. The zero-markup drug policy removed a major drug revenue channel, while DRG/DIP reforms seek to reduce itemized inpatient billing incentives. Medical service pricing reform is intended to better reflect technical labor while controlling inappropriate cost growth.
Operating model
Fee-for-service can reward activity more than value. Hospitals may have incentives to increase admissions, tests, procedures, or prescriptions when payment is tied to each item. Removing one revenue source can shift behavior unless compensation, salaries, service prices, and payment methods are redesigned together. This is why fee-for-service cannot be understood apart from public hospital compensation reform.
Strategic reading
For market access, fee-for-service can create easier adoption for billable products but can also make the product vulnerable when payment reform arrives. Companies should ask whether demand is driven by real clinical value or by a billing incentive. If the business case disappears under DRG/DIP or price reform, the product is exposed.
Decision test
For Fee-for-Service in China, the practical test is whether the analysis identifies the payer rule, hospital incentive, procurement route, affected product category, and implementation level. A page that only says China wants lower prices is not useful. The specific question is who changes behavior, under which rule, with what price, budget, quality, and access consequence.
Implementation detail
Fee-for-Service in China should be read through the full chain of Chinese healthcare finance: policy design, provincial or national implementation, hospital operating response, department-level behavior, and patient access. A reform can lower headline prices while still creating new questions about quality, supply, service availability, hospital incentives, and whether the savings reach patients in the form of usable care. The relevant evidence is therefore not only the announced policy, but also how hospitals, manufacturers, physicians, distributors, and insurers respond after implementation.
For market access, the page is most useful when it separates four layers. The first is the formal rule: who issued it, which products or services it covers, and when it applies. The second is the payment consequence: who loses margin, gains volume, absorbs cost, or changes budget risk. The third is the clinical consequence: whether physicians and hospitals can still choose the product, service, or workflow that fits the patient. The fourth is the commercialization consequence: whether a company should compete, differentiate, localize, redesign the channel, gather new evidence, or avoid the category. Without those layers, payment and procurement reform sounds abstract even though it directly determines adoption.